MoonLake Immunotherapeutics - Class A MLTX

NAS: MLTX | ISIN: KY61559X1045   6/05/2024
44,52 USD (-1,63%)
(-1,63%)   6/05/2024
Grafiek MoonLake Immunotherapeutics - Class A Grafiek MoonLake Immunotherapeutics - Class A

MoonLake Immunotherapeutics - Class A in het nieuws

10 maart 2024 · MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day · Persbericht

4 maart 2024 · MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 · Persbericht

29 februari 2024 · MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 · Persbericht

26 februari 2024 · MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) · Persbericht

14 november 2023 · MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update · Persbericht

5 november 2023 · MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis · Persbericht

15 oktober 2023 · MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa · Persbericht

11 oktober 2023 · MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress · Persbericht

6 september 2023 · MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 · Persbericht

10 augustus 2023 · MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update · Persbericht

Profiel MoonLake Immunotherapeutics - Class A

moonlake immunotherapeutics ag is een biofarmaceutisch bedrijf in een klinische fase dat gebruikmaakt van revolutionaire nanobody®-technologie voor de ontwikkeling van nieuwe geneesmiddelen voor immunologische ziekten, waaronder inflammatoire huid- en gewrichtsziekten.

Werknemers: 14

Aandelen MoonLake Immunotherapeutics - Class A

Beurswaarde: 2,85 miljard USD

Effecten: 62,87 miljoen

Beta: 0,50

Mijn selecties